Literature DB >> 1452744

Primary epiphyseal transplants and bone overgrowth in childhood amputations.

J Benevenia1, J T Makley, M C Leeson, K Benevenia.   

Abstract

Seventeen children aged newborn to 14 years underwent major through-bone amputations or revision at our two institutions. Ten patients (group 1) had primary autogenous epiphyseal transplants taken from the amputated limb and used to cap the open medullary canal of the residual limb. Seven patients (group 2) did not have epiphyseal transplants. Nine of 10 patients in group 1 (90%) had no problems related to bone overgrowth or delay in prosthetic fitting. In group 2, six of seven patients (86%) had clinically symptomatic bony overgrowth of 20 months after the index amputation on the average. Four patients had surgical revisions. Therefore, provided healthy autogenous donor epiphyses are available, we recommend primary epiphyseal transplants to avoid the complications of bone overgrowth in childhood through-bone amputations.

Entities:  

Mesh:

Year:  1992        PMID: 1452744     DOI: 10.1097/01241398-199211000-00009

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  4 in total

1.  Transtibial Ertl amputation for children and adolescents: a case series and literature review.

Authors:  Gregory Bodley Firth; Julio Javier Masquijo; Ken Kontio
Journal:  J Child Orthop       Date:  2011-09-06       Impact factor: 1.548

2.  Skeletal scintigraphic appearance of an auto-transplanted osteoarticular plug: epiphyseal transplant.

Authors:  Stuart C Morrison; John T Makley; James O'Donnell
Journal:  Pediatr Radiol       Date:  2003-04-26

Review 3.  Inflammation in bone physiology and pathology.

Authors:  Iannis E Adamopoulos
Journal:  Curr Opin Rheumatol       Date:  2018-01       Impact factor: 5.006

4.  Acute femoral shortening for reconstruction of a complex lower extremity crush injury.

Authors:  Philip K Lim; Bharat Sampathi; Nathan M Moroski; John A Scolaro
Journal:  Strategies Trauma Limb Reconstr       Date:  2018-05-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.